research Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
This study suggests that adopting the Mark Cuban Cost Plus Drug Company model for purchasing urological medications could have saved Medicare about $1.29 billion in 2020.


